Enveric Biosciences Showcases EB-003 Data at 7th Neuropsychiatric Drug Summit

Enveric Biosciences, a biotechnology company listed on NASDAQ under the ticker ENVB, has announced that research on its lead compound, EB-003, will be presented at the 7th Neuropsychiatric Drug Summit. The summit, taking place at the Hilton Boston Back Bay from September 24-26, 2024, will showcase the potential of EB-003, a neuroplastogenic and non-hallucinogenic analog of N,N-Dimethyltryptamine (DMT), in treating anxiety and depression.

The presentation, titled “Non-hallucinogenic and neuroplastogenic DMT analog imparts positive behavioral outcomes in mice,” will highlight various preclinical studies conducted on EB-003. These studies include two mouse models that demonstrate positive results in reducing anxiety and depression. Additionally, the research delves into the head twitch response (HTR), a behavioral indicator in rodents that parallels hallucinogenic effects in humans. The positive outcomes of these preclinical tests underscore EB-003's potential in treating neuropsychiatric conditions without inducing hallucinations.

Enveric Biosciences has recently reported data confirming that EB-003 has oral bioavailability and can achieve brain exposure at levels therapeutic for treatment. The company has ambitious plans to file an Investigational New Drug (IND) application for EB-003 by the third quarter of 2025, aiming to commence clinical trials by the end of that year.

Dr. Joseph Tucker, CEO of Enveric, emphasized the significance of the research being presented at the Neuropsychiatric Drug Summit. According to Dr. Tucker, the foundational studies on EB-003 were instrumental in selecting it as the lead product candidate. The compound's potential to treat resistant mental health disorders without the hallucinogenic side effects typically associated with DMT-based drugs sets it apart. He added that recent evidence supporting its optimal brain exposure after oral dosing further strengthens the belief in EB-003’s unique therapeutic potential. Dr. Tucker stated that EB-003 could become a significant value driver for both Enveric and its shareholders.

Enveric Biosciences focuses on developing novel neuroplastogenic small-molecule therapeutics aimed at treating depression, anxiety, and addiction disorders. The company leverages its innovative discovery and development platform, Psybrary™, to build a robust intellectual property portfolio of new chemical entities targeting specific mental health conditions. Besides EB-003, Enveric is also developing EB-002, a next-generation synthetic prodrug of psilocin, which is being explored as a treatment for psychiatric disorders.

Headquartered in Naples, Florida, with offices in Cambridge, Massachusetts, and Calgary, Alberta, Canada, Enveric Biosciences is at the forefront of creating cutting-edge treatments for challenging mental health issues. By focusing on non-hallucinogenic therapeutic options, Enveric aims to advance the field of neuropsychiatric treatment and provide new hope for patients struggling with resistant mental health disorders.